---
title: "LivaNova PLC 1Q 2026: Revenue $362.26M, EPS $0.4— 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285415392.md"
description: "LivaNova PLC reported a revenue of $362.26M for Q1 2026, marking a 14.3% increase from the previous year, with a diluted EPS of $0.4 compared to a loss of $6.01 in Q1 2025. The company achieved a net income of $22.29M, recovering from a loss of $327.32M a year ago. Growth was driven by strong demand in the U.S. and Europe, particularly in the cardiopulmonary and neuromodulation segments. R&D investments increased to support new developments, while operations remained stable despite global challenges."
datetime: "2026-05-06T17:11:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285415392.md)
  - [en](https://longbridge.com/en/news/285415392.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285415392.md)
---

# LivaNova PLC 1Q 2026: Revenue $362.26M, EPS $0.4— 10-Q Summary

LivaNova PLC reported first-quarter 2026 results with revenue of $362.26M, up 14.3% from the prior-year quarter, and diluted EPS of $0.4 versus ($6.01) in 1Q 2025; the company returned to net income of $22.29M after a loss in the year-ago quarter. — 10-Q Summary

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$362.26M

$316.86M

14.3%

Net income²

$22.29M

($327.32M)

106.8%

Diluted EPS³

$0.4

($6.01)

106.7%

_¹ Reported as “Net revenue”. ² Reported as “Net income (loss)”. ³ Reported as “Diluted earnings (loss) per share”._

**Business Highlights**

-   Revenue growth was broad-based across channels and regions, with notable strength in the U.S., Europe (26.7% YoY) and the Rest of World driven by consumables and implant demand.
-   Cardiopulmonary segment growth was led by demand for the Essenz Perfusion System, while Neuromodulation benefited from higher VNS Therapy implant volumes.
-   R&D investment increased to support OSA neurostimulation development; contingent consideration items tied to milestones affected results.
-   Operations remained resilient with supply-chain and logistics mitigation keeping production intact despite macro and global constraints.

Original SEC Filing: LivaNova PLC \[ LIVN \] - 10-Q - May. 06, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [LIVN.US](https://longbridge.com/en/quote/LIVN.US.md)

## Related News & Research

- [LivaNova Shareholders Back 2026 AGM Proposals and Governance](https://longbridge.com/en/news/289482760.md)
- [Is LivaNova’s (LIVN) Boardroom Refresh Quietly Reframing Its Long-Term Risk and Strategy Playbook?](https://longbridge.com/en/news/289671374.md)
- [Jette Nygaard-Andersen Joins LivaNova Board as a New Director | LIVN Stock News](https://longbridge.com/en/news/289499287.md)
- [Rhenman & Partners Asset Management AB Purchases 137,000 Shares of LivaNova PLC $LIVN](https://longbridge.com/en/news/289661768.md)
- [Germany April industrial production +0.4% vs +0.5% m/m expected](https://longbridge.com/en/news/289143205.md)